VOM Lips Regulatory Status: A Comprehensive Guide for Professionals

VOM Lips is a hyaluronic acid dermal filler originating from South Korea, manufactured by CG Bio. Designed for professional use, its availability and suitability for your clinic depend significantly on its regulatory compliance within your operational region. Professionals seeking to source products like VOM Lips must prioritize verifiable certifications to ensure adherence to local and international standards. When evaluating options within the hyaluronic acid dermal filler catalog, regulatory standing is a primary consideration.

Illustrative wholesale pricing for VOM Lips stands at $57.4 per unit, with tiered volume discounts: 11 units yield 4% off, 21 units yield 5% off, 31 units yield 6% off, and 51+ units yield 8% off.

As a product manufactured in South Korea, VOM Lips is typically subject to the stringent regulatory oversight of the KFDA (Korean Ministry of Food and Drug Safety). This national approval indicates compliance with South Korean standards for medical devices. Beyond KFDA, manufacturers like CG Bio are expected to adhere to GMP (Good Manufacturing Practices) guidelines, which ensure product consistency and quality control. ISO (International Organization for Standardization) certifications, such as ISO 13485 for medical device quality management systems, further reinforce the manufacturing integrity of the product. Verifying these foundational certifications is a crucial first step for any professional buyer.

Accessing international markets requires adherence to diverse regulatory frameworks. For the European Union, the CE Mark is generally mandatory for medical devices like VOM Lips, signifying conformity with EU health, safety, and environmental protection standards. For the UK, the UKCA Mark (UK Conformity Assessed) has become relevant post-Brexit. The specific CE/UKCA status for VOM Lips requires direct verification from the manufacturer or official regulatory databases [VERIFY: VOM Lips CE Mark / UKCA status]. Similarly, market entry into regions like the GCC, LATAM, and APAC depends on individual country-specific registrations and approvals, which may vary significantly.

The United States market operates under the strict purview of the FDA (Food and Drug Administration). For hyaluronic acid dermal fillers, FDA approval is a rigorous process involving extensive clinical data and manufacturing facility inspections. Without specific FDA clearance or approval, a product cannot be legally marketed or distributed within the United States. Professionals must ascertain the exact FDA status of VOM Lips if they intend to operate within this jurisdiction [VERIFY: VOM Lips FDA status].

The global market for aesthetic injectables often involves parallel imports, which can introduce risks regarding product authenticity and traceability. While legal in some regions under specific conditions, sourcing through unauthorized channels can compromise product integrity and patient safety. Professionals should exercise extreme caution, ensuring that their supply chain is transparent and authorized. This diligence is comparable to the rigorous verification processes detailed in our guide on Verifying Genuine Xeomin 50 Units: A Guide for Aesthetic Pro.

To mitigate risks, clinic owners and aesthetic professionals must demand specific documentation from their suppliers. This includes proof of regulatory approvals relevant to their market (e.g., KFDA, CE Mark if applicable). Essential supplier documentation also encompasses lot numbers for traceability, original manufacturer certificates, and evidence of proper storage and cold chain management where required. Always verify that your supplier is authorized to distribute VOM Lips or similar D.Fill Soft products within your region, as outlined in guides like Lapuroon Aurora Super Wholesale: A Procurement Guide for Aes.